Half-life determination of 155Tb from mass-separated samples produced at CERN-MEDICIS

S.M. Collins; Andrew P. Robinson; P. Ivanov; Ulli Köster; Thomas Elias Cocolios; Ben Russel; B. Webster; Andrew J. Fenwick; Charlotte Duchemin; João Pedro Fernandes Pinto Ramos; Eric Chevallay; Ulrika Jakobsson; Simon Stegemann; P.H.  Regan; Thierry Stora

doi:10.1016/j.apradiso.2022.110480

Half-life determination of 155Tb from mass-separated samples produced at CERN-MEDICIS

S.M. Collins, Andrew P. Robinson, P. Ivanov, Ulli Köster, Thomas Elias Cocolios, Ben Russel, B. Webster, Andrew J. Fenwick, Charlotte Duchemin, João Pedro Fernandes Pinto Ramos, Eric Chevallay, Ulrika Jakobsson, Simon Stegemann, P.H. Regan, Thierry Stora

Research output › peer-review

Abstract

Terbium-155 has been identified for its potential for single-photon emission computed tomography (SPECT) in nuclear medicine. For activity measurements, an accurate and precise half-life of this radionuclide is required. However, the currently evaluated half-life of 5.32(6) d with a relative standard uncertainty of 1.1% determines the precision possible. Limited literature for the half-life measurements of this radionuclide is available and all reported investigations are prior to 1970. Further measurements are therefore needed to confirm the accuracy and improve the precision of the half-life for its use in the clinical setting. Two samples produced and mass separated at the CERN-MEDICIS facility have been measured at the National Physical Laboratory by two independent techniques: liquid scintillation counting and high-purity germanium gamma-ray spectrometry. A half-life of 5.2346(36) d has been determined from the weighted mean of the half-lives determined by the two techniques. The half-life reported in this work has shown a relative difference of 1.6% to the currently evaluated half-life and has vastly improved the precision.

Original language	English
Article number	110480
Number of pages	11
Journal	Applied Radiation and Isotopes
Volume	190
DOIs	https://doi.org/10.1016/j.apradiso.2022.110480
State	Published - Dec 2022

Access to Document

10.1016/j.apradiso.2022.110480License:

Cite this

Collins, S. M., Robinson, A. P., Ivanov, P., Köster, U., Cocolios, T. E., Russel, B., Webster, B., Fenwick, A. J., Duchemin, C., Fernandes Pinto Ramos, J. P., Chevallay, E., Jakobsson, U., Stegemann, S., Regan, P. H., & Stora, T. (2022). Half-life determination of 155Tb from mass-separated samples produced at CERN-MEDICIS. Applied Radiation and Isotopes, 190, Article 110480. https://doi.org/10.1016/j.apradiso.2022.110480

@article{b389f4882b894bb5bd3e8c76e837746b,

title = "Half-life determination of 155Tb from mass-separated samples produced at CERN-MEDICIS",

abstract = "Terbium-155 has been identified for its potential for single-photon emission computed tomography (SPECT) in nuclear medicine. For activity measurements, an accurate and precise half-life of this radionuclide is required. However, the currently evaluated half-life of 5.32(6) d with a relative standard uncertainty of 1.1% determines the precision possible. Limited literature for the half-life measurements of this radionuclide is available and all reported investigations are prior to 1970. Further measurements are therefore needed to confirm the accuracy and improve the precision of the half-life for its use in the clinical setting. Two samples produced and mass separated at the CERN-MEDICIS facility have been measured at the National Physical Laboratory by two independent techniques: liquid scintillation counting and high-purity germanium gamma-ray spectrometry. A half-life of 5.2346(36) d has been determined from the weighted mean of the half-lives determined by the two techniques. The half-life reported in this work has shown a relative difference of 1.6% to the currently evaluated half-life and has vastly improved the precision.",

keywords = "155Tb, Mass separation, Half-life, Medicis",

author = "S.M. Collins and Robinson, {Andrew P.} and P. Ivanov and Ulli K{\"o}ster and Cocolios, {Thomas Elias} and Ben Russel and B. Webster and Fenwick, {Andrew J.} and Charlotte Duchemin and {Fernandes Pinto Ramos}, {Jo{\~a}o Pedro} and Eric Chevallay and Ulrika Jakobsson and Simon Stegemann and P.H. Regan and Thierry Stora",

note = "Score=10",

year = "2022",

month = dec,

doi = "10.1016/j.apradiso.2022.110480",

language = "English",

volume = "190",

journal = "Applied Radiation and Isotopes",

issn = "0969-8043",

publisher = "Elsevier",

}

Collins, SM, Robinson, AP, Ivanov, P, Köster, U, Cocolios, TE, Russel, B, Webster, B, Fenwick, AJ, Duchemin, C, Fernandes Pinto Ramos, JP, Chevallay, E, Jakobsson, U, Stegemann, S, Regan, PH & Stora, T 2022, 'Half-life determination of 155Tb from mass-separated samples produced at CERN-MEDICIS', Applied Radiation and Isotopes, vol. 190, 110480. https://doi.org/10.1016/j.apradiso.2022.110480

TY - JOUR

T1 - Half-life determination of 155Tb from mass-separated samples produced at CERN-MEDICIS

AU - Collins, S.M.

AU - Robinson, Andrew P.

AU - Ivanov, P.

AU - Köster, Ulli

AU - Cocolios, Thomas Elias

AU - Russel, Ben

AU - Webster, B.

AU - Fenwick, Andrew J.

AU - Duchemin, Charlotte

AU - Fernandes Pinto Ramos, João Pedro

AU - Chevallay, Eric

AU - Jakobsson, Ulrika

AU - Stegemann, Simon

AU - Regan, P.H.

AU - Stora, Thierry

N1 - Score=10

PY - 2022/12

Y1 - 2022/12

N2 - Terbium-155 has been identified for its potential for single-photon emission computed tomography (SPECT) in nuclear medicine. For activity measurements, an accurate and precise half-life of this radionuclide is required. However, the currently evaluated half-life of 5.32(6) d with a relative standard uncertainty of 1.1% determines the precision possible. Limited literature for the half-life measurements of this radionuclide is available and all reported investigations are prior to 1970. Further measurements are therefore needed to confirm the accuracy and improve the precision of the half-life for its use in the clinical setting. Two samples produced and mass separated at the CERN-MEDICIS facility have been measured at the National Physical Laboratory by two independent techniques: liquid scintillation counting and high-purity germanium gamma-ray spectrometry. A half-life of 5.2346(36) d has been determined from the weighted mean of the half-lives determined by the two techniques. The half-life reported in this work has shown a relative difference of 1.6% to the currently evaluated half-life and has vastly improved the precision.

AB - Terbium-155 has been identified for its potential for single-photon emission computed tomography (SPECT) in nuclear medicine. For activity measurements, an accurate and precise half-life of this radionuclide is required. However, the currently evaluated half-life of 5.32(6) d with a relative standard uncertainty of 1.1% determines the precision possible. Limited literature for the half-life measurements of this radionuclide is available and all reported investigations are prior to 1970. Further measurements are therefore needed to confirm the accuracy and improve the precision of the half-life for its use in the clinical setting. Two samples produced and mass separated at the CERN-MEDICIS facility have been measured at the National Physical Laboratory by two independent techniques: liquid scintillation counting and high-purity germanium gamma-ray spectrometry. A half-life of 5.2346(36) d has been determined from the weighted mean of the half-lives determined by the two techniques. The half-life reported in this work has shown a relative difference of 1.6% to the currently evaluated half-life and has vastly improved the precision.

KW - 155Tb

KW - Mass separation

KW - Half-life

KW - Medicis

UR - https://ecm.sckcen.be/OTCS/llisapi.dll/open/52901406

U2 - 10.1016/j.apradiso.2022.110480

DO - 10.1016/j.apradiso.2022.110480

M3 - Article

SN - 0969-8043

VL - 190

JO - Applied Radiation and Isotopes

JF - Applied Radiation and Isotopes

M1 - 110480

ER -